
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of marstacimab (Hympavzi) for treating bleeding episodes in people aged 12 years or older with severe hemophilia A and B.


coremsg

The drug will be available for patients aged 12 years and older and weighing at least 35 kg.

Hympavzi Recommended for Approval in Europe for Severe Hemophilia A, B

marstacimab-hympavzi-recommended-for-approval-in-europe-for-treating-severe-hemophilia-a-and-b


Marstacimab (Hympavzi) Recommended for Approval in Europe for Treating Severe Hemophilia A and B
